EUVIMEDEUVIMED entdecken
Crossref

FOXA1-mediated transcription of MFAP2 facilitates cell growth, metastasis and cisplatin resistance in uterine corpus endometrial carcinoma

Jie Bai, Jing Bai, Hongzhen Zhang

Naunyn-Schmiedeberg's Archives of Pharmacology · 2025

DOI: 10.1007/s00210-025-04041-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2025. Verfasst von Jie Bai und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. Hauptthemen laut MEDLINE: Hepatocyte Nuclear Factor 3-alpha, Cisplatin, Drug Resistance, Neoplasm, Endometrial Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Microfibril-associated protein 2 (MFAP2) has been confirmed to be an oncogene to participate in regulating the progression of many cancers. However, its role and mechanism in the development of uterine corpus endometrial carcinoma (UCEC) are still unclear. The mRNA and protein levels of MFAP2 and forkhead box A1 (FOXA1) were determined using qRT-PCR and western blot. Cell proliferation, apoptosis, migration, invasion and cisplatin resistance were detected by colony formation assay, EdU assay, flow cytometry, transwell assay and CCK8 assay. Xenograft tumor models were constructed to explore the effect of MFAP2 knockdown on UCEC tumorigenesis and cisplatin resistance in vivo. The interaction between FOXA1 and MFAP2 promoter was evaluated by ChIP assay and dual-luciferase reporter assay. MFAP2 was upregulated in UCEC tissues and cells. Silencing of MFAP2 repressed UCEC cell growth, metastasis and cisplatin resistance in vitro, as well as reduced tumorigenesis in vivo. In terms of mechanism, FOXA1 bound to MFAP2 promoter region to increase its expression. FOXA1 knockdown could inhibit UCEC cell growth, metastasis and cisplatin resistance. Moreover, FOXA1 promoted growth, metastasis and cisplatin resistance in UCEC cells via enhancing MFAP2 expression. FOXA1-activated MFAP2 might contribute to the growth, metastasis and cisplatin resistance of UCEC cells, providing a novel target for UCEC treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatocyte Nuclear Factor 3-alphaCisplatinDrug Resistance, NeoplasmEndometrial NeoplasmsAntineoplastic AgentsCytoskeletal ProteinsFemaleHumansAnimalsCell ProliferationCell Line, TumorMice, NudeMiceMice, Inbred BALB CGene Expression Regulation, NeoplasticCell MovementApoptosisPromoter Regions, Genetic

Stichwörter der Autor:innen

FOXA1MFAP2Uterine corpus endometrial carcinoma

Substanzen

Hepatocyte Nuclear Factor 3-alphaCisplatinFOXA1 protein, humanAntineoplastic AgentsCytoskeletal Proteins

Autor:innen und Institutionen

  • Department of Gynecology, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
  • Department of Obstetrics and Gynecology, North China University of Science and Technology Affiliated Hospital, Tangshan, Hebei, China.
  • Department of Anesthesiology, North China University of Science and Technology Affiliated Hospital, Tangshan, 063000, Hebei Province, China.
  • Department of Gynecology, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. zhz0827@hebmu.edu.cn.

Zitieren

APA

Bai, J., Bai, J., & Zhang, H. (2025). FOXA1-mediated transcription of MFAP2 facilitates cell growth, metastasis and cisplatin resistance in uterine corpus endometrial carcinoma. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-025-04041-x

Vancouver

Bai J, Bai J, Zhang H. FOXA1-mediated transcription of MFAP2 facilitates cell growth, metastasis and cisplatin resistance in uterine corpus endometrial carcinoma. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025. doi:10.1007/s00210-025-04041-x

BibTeX
@article{Bai2025,
  author = {Bai, Jie and Bai, Jing and Zhang, Hongzhen},
  title = {FOXA1-mediated transcription of MFAP2 facilitates cell growth, metastasis and cisplatin resistance in uterine corpus endometrial carcinoma},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2025},
  doi = {10.1007/s00210-025-04041-x}
}
Kostenlos starten →